^
Association details:
| Biomarker: | ATF7IP-PDGFRB fusion |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report
Excerpt:
…our patient with a variant ATF7IP/PDGFRB fusion had a poor initial treatment response to chemotherapy but responded well to TKI-based therapy and is now doing well in continuous remission…. The patient is now receiving the Chinese Children’s Cancer Group (CCCG)-2015-ALL protocol plus dasatinib and remains free of molecularly detectable disease.
DOI:
10.12659/AJCR.906300
